CIK 0000906709
- Non-accelerated filer
- Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943134940
- Phone
- +1 415-482-5300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-11-15 | ROBIN HOWARD W President & CEO | Grant or award · Stock Option | +137,500 | 137,500 | ||
| 2017-11-15 | Nicholson John SVP & Chief Operating Officer | Grant or award | +20,000 | 253,156 | ||
| 2017-11-15 | Nicholson John SVP & Chief Operating Officer | Grant or award · Stock Option | +50,000 | 50,000 | ||
| 2017-11-15 | Labrucherie Gil M SVP & Chief Financial Officer | Grant or award | +20,000 | 83,414 | ||
| 2017-11-15 | Labrucherie Gil M SVP & Chief Financial Officer | Grant or award · Stock Option | +50,000 | 50,000 | ||
| 2017-11-15 | Hora Maninder SVP Pharma Dev & Mfg Ops | Grant or award | +15,000 | 73,233 | ||
| 2017-11-15 | Hora Maninder SVP Pharma Dev & Mfg Ops | Grant or award · Stock Option | +37,500 | 37,500 | ||
| 2017-11-15 | Gergel Ivan P. SVP & Chief Medical Officer | Grant or award | +20,000 | 61,575 | ||
| 2017-11-15 | Gergel Ivan P. SVP & Chief Medical Officer | Grant or award · Stock Option | +50,000 | 50,000 | ||
| 2017-11-15 | Doberstein Stephen K SVP & Chief Scientific Officer | Grant or award | +17,500 | 48,602 | ||
| 2017-11-15 | Doberstein Stephen K SVP & Chief Scientific Officer | Grant or award · Stock Option | +43,750 | 43,750 | ||
| 2017-11-13 | Nicholson John SVP & Chief Operating Officer | Exercise or conversion | +25,000 | $9.24 | $231K | 249,066 |
| 2017-11-13 | Nicholson John SVP & Chief Operating Officer | Sale | −15,910 | $37.78 | $601K | 233,156 |
| 2017-11-13 | Nicholson John SVP & Chief Operating Officer | Exercise or conversion · Stock Option | −25,000 | 0 | ||
| 2017-11-08 | Doberstein Stephen K SVP & Chief Scientific Officer | Exercise or conversion | +300,000 | $9.53 | $2.9M | 331,102 |
| 2017-11-08 | Doberstein Stephen K SVP & Chief Scientific Officer | Sale | −300,000 | $30.09 | $9.0M | 31,102 |
| 2017-11-08 | Doberstein Stephen K SVP & Chief Scientific Officer | Exercise or conversion · Stock Option | −300,000 | 0 | ||
| 2017-11-07 | Hora Maninder SVP Pharma Dev & Mfg Ops | Exercise or conversion | +17,300 | $10.69 | $185K | 75,533 |
| 2017-11-07 | Hora Maninder SVP Pharma Dev & Mfg Ops | Exercise or conversion | −17,300 | $25.51 | $441K | 58,233 |
| 2017-11-07 | Hora Maninder SVP Pharma Dev & Mfg Ops | Exercise or conversion · Stock Option | −17,300 | 0 |
Page 38 of 43 · 847 trades